IGFBP2 and cancer: Differences in circulating IGF-1 and its inhibitors (IGFBP-2 and IGFBP-3) have been associated with the risk of several cancers, thus proposing these indicators as non-invasive biomarkers for cancer risk and prognosis [7,8,9].